Journals

NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.

The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.

The Journal of Clinical Oncology is ASCO's flagship journal and the workhorse of clinical oncology, publishing trials, ASCO guidelines, and the abstract supplements for the ASCO Annual Meeting.

Nature is the world's leading multidisciplinary science journal. The big cancer biology discoveries land here: cancer genome atlases, tumour evolution, new drug targets and early first-in-human results.

Science is the AAAS flagship and Nature's main rival. It is home to landmark cancer papers on mismatch repair and immunotherapy, cancer genome sequencing, liquid biopsy and the microbiome.

The BMJ is the British Medical Association's journal. It published Doll and Hill's 1950 smoking and lung cancer study and remains a leading critic of weak cancer-drug evidence and a champion of open data.

Cell is the leading molecular and cell biology journal. It published the Hallmarks of Cancer and much of the mechanistic biology behind today's cancer drugs.

Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.

The Lancet Oncology is the leading specialist cancer journal for clinical trials. It publishes phase 2 and 3 trials, long-term follow-up, quality-of-life analyses and global-oncology policy Commissions.

JAMA is the American Medical Association's flagship journal. It is strong on cancer screening, prevention, health-services and patient-reported-outcome research, and on the USPSTF recommendations.

JAMA Internal Medicine is the JAMA Network's internal-medicine journal, known for sceptical, evidence-based analyses of overdiagnosis, surrogate endpoints and low-value care in cancer.

PNAS is the US National Academy of Sciences' multidisciplinary journal, home to many foundational cancer biology and cancer-modelling papers.

AACR's high-profile journal bridging discovery and the clinic: first-in-human targeted-therapy data, resistance mechanisms and translational biology.

A high-volume open-access oncology journal from MDPI publishing thousands of papers a year across basic, translational and clinical cancer research.

AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.

A non-profit open-access life-science journal backed by HHMI, Wellcome and the Max Planck Society, known for its reviewed-preprint publishing model.

JNCI began as the US National Cancer Institute's own journal and is now independent. It is strong on cancer epidemiology, screening, trial methodology and health disparities.

Annals of Internal Medicine is the American College of Physicians' journal, important in cancer for screening guidance, modelling studies and systematic reviews that inform primary care.

Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.

bioRxiv is the preprint server for biology. Most cancer genomics, immunology and computational papers now appear here before the journal version.

Blood is the American Society of Hematology's flagship journal, covering leukaemia, lymphoma, myeloma and transplant biology and trials, plus the ASH annual meeting abstracts.

ASH's fully open-access journal for haematology, including real-world outcomes, phase 1 and 2 trials and the ASH clinical practice guidelines.

Cancer Research UK's journal: translational and clinical cancer research plus the UK epidemiology on cancer risk factors and attributable fractions.

CA: A Cancer Journal for Clinicians has the highest impact factor of any journal, because it publishes the annual US and global cancer statistics that almost every cancer paper cites.

Cancer is the American Cancer Society's peer-reviewed clinical journal, publishing across all cancers since 1948 with a focus on epidemiology, survivorship and outcomes.

Cancer Cell is Cell Press's dedicated cancer journal, publishing mechanism-rich papers on tumour biology, the microenvironment, resistance and biomarkers, plus the CPTAC proteogenomic atlases.

AACR's epidemiology and prevention journal: risk factors, screening, early-detection biomarkers and cancer disparities.

AACR's tumour immunology journal: mechanisms of immune response and escape, checkpoint and cell-therapy biology and immune biomarkers.

Cancer Research is AACR's original journal, publishing since 1941: broad basic and preclinical cancer biology, tumour immunology and the AACR annual meeting abstracts.

Cell Press's stem-cell journal, relevant to cancer for leukaemia stem cells, clonal haematopoiesis, organoid models and off-the-shelf cell therapies.

Clinical Pharmacology & Therapeutics is the ASCPT journal for dose optimisation, pharmacokinetics, drug interactions and pharmacogenomics, increasingly central to how oncology doses are chosen after FDA's Project Optimus.

ESMO's fully open-access journal: trials, real-world studies, ESMO position papers and the Living Guidelines updates, all free to read.

The European Journal of Cancer is the EORTC-affiliated European journal for clinical and translational cancer research, notable for melanoma, sarcoma, quality-of-life and European guideline work.

European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.

European Urology Oncology is the European Association of Urology's dedicated cancer journal for prostate, bladder, kidney and testicular cancer research.

A Cold Spring Harbor molecular biology journal where much of the foundational work on oncogenes, tumour suppressors, senescence and cancer gene regulation was published.

Gynecologic Oncology is the Society of Gynecologic Oncology's journal for ovarian, endometrial, cervical and vulvar cancer research, surgery and PARP-inhibitor and immunotherapy trials.

The European Hematology Association's open-access journal, publishing haematological malignancy research from Europe and worldwide with no paywall.

ASTRO's journal, the Red Journal: the main US venue for radiation oncology trials, dose-fractionation evidence, physics and toxicity research.

JAMA Oncology is the JAMA Network's cancer journal, publishing phase 2 trials, secondary analyses of big trials, epidemiology, health policy and drug-pricing research.

ASCO's journal about how cancer care is actually delivered and paid for: financial toxicity, workforce, quality measures, telehealth and payment reform.

ASCO's journal for genomics-guided cancer care: tumour sequencing studies, biomarker-selected trials, molecular tumour board case series and real-world genomic data.

SITC's fully open-access journal: checkpoint-inhibitor and cell-therapy trials, immune-related toxicity management guidelines and immunotherapy biomarkers.

The Journal of Clinical Investigation is a century-old physician-scientist journal, free to read, publishing mechanistic disease biology including tumour immunology, metabolism and early CAR-T science.

The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.

JNCCN is the NCCN's journal, where the US treatment guidelines are published in article form alongside real-world practice and cost studies.

The Journal of Thoracic Oncology is the IASLC's journal and the leading specialist venue for lung cancer and mesothelioma: staging, biomarkers, targeted-therapy and screening research.

Leukemia is a Springer Nature haematology journal covering leukaemia, lymphoma and myeloma biology and clinical research, including the International Myeloma Working Group consensus papers.

medRxiv is the preprint server for medicine and health sciences. Clinical cancer studies appear here weeks or months before journal publication, unreviewed.

AACR's preclinical therapeutics journal: where new small molecules, ADCs and combination strategies are first characterised in cells and mice.

Nature Biotechnology is the leading biotechnology journal, covering new sequencing and single-cell methods, CAR-T and gene-editing engineering, ADC and protein design, plus biotech industry analysis.

Nature Cancer is Nature's cancer-specific research journal, launched in 2020, spanning basic biology to translational and clinical cancer studies.

Springer Nature's large fully open-access multidisciplinary journal, carrying a high volume of cancer genomics, immunology, AI and translational papers.

Nature Genetics is the top genetics journal, publishing cancer genome-wide association studies, polygenic risk scores, cancer gene discovery and mutational-signature work.

Commissioned expert reviews on cancer biology. The place to start when learning a new area of tumour biology, from metabolism to metastasis.

Commissioned clinical reviews for oncologists: treatment landscapes, biomarker strategies and trial-design critique, with the highest impact factor of any oncology journal.

Reviews and industry analysis on how drugs are discovered and developed, including the pipeline and success-rate data widely cited for oncology.

NEJM Group's newer journal for clinical trials and trial methodology, publishing rigorous randomised studies that fall just outside the parent journal's remit.

Neuro-Oncology is the Society for Neuro-Oncology's journal, publishing glioma, brain metastasis and paediatric brain tumour research, response criteria and the CBTRUS statistical reports.

Pediatric Blood & Cancer is the joint ASPHO and SIOP journal for childhood cancer and blood disorders, publishing cooperative-group trial reports, late effects and supportive care.

A fully open-access general medical journal that favours studies with global public-health impact, including cancer epidemiology, screening and health-policy work.

Radiology is the RSNA's flagship journal, publishing imaging research including cancer screening performance, AI image analysis and response assessment.

ESTRO's journal, known as the Green Journal: European radiotherapy trials, contouring guidelines, physics and the evidence base for hypofractionation and proton therapy.

Science Translational Medicine is AAAS's translational journal, publishing the bench-to-bedside cancer papers on liquid biopsy, CAR-T engineering, tumour-immune biology and new imaging agents.

The Lancet's open-access digital-health journal: AI diagnostics, pathology and radiology algorithms, prediction models and the reporting standards for them.

The Lancet's open-access global-health journal: where the numbers on cancer burden, survival gaps and treatment access in low- and middle-income countries are published.

The Lancet Haematology is the Lancet's haematology journal, publishing phase 2 and 3 trials in leukaemia, lymphoma and myeloma, transplant studies and global-access commentary on blood cancers.